These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 9299630)
21. Nigericin is a potent inhibitor of the early stage of vaccinia virus replication. Myskiw C; Piper J; Huzarewich R; Booth TF; Cao J; He R Antiviral Res; 2010 Dec; 88(3):304-10. PubMed ID: 20951746 [TBL] [Abstract][Full Text] [Related]
22. Selective inhibition of pyrimidine synthesis and depletion of nucleotide pools by N-(phosphonacetyl)-L-aspartate. Moyer JD; Handschumacher RE Cancer Res; 1979 Aug; 39(8):3089-94. PubMed ID: 455293 [No Abstract] [Full Text] [Related]
23. Evaluation of the antiviral activity of N-(phosphonoacetyl)-L-aspartate against paramyxoviruses in tissue culture and against respiratory syncytial virus in cotton rats. Wyde PR; Moore DK; Pimentel DM; Blough HA Antiviral Res; 1995 May; 27(1-2):59-69. PubMed ID: 7486959 [TBL] [Abstract][Full Text] [Related]
24. Single-strand breaks in DNA by 1-beta-D-arabinofuranosylcytosine and enhanced resistance frequency to N-phosphonoacetyl-L-aspartate. Chen Y; Goz B Anticancer Res; 1991; 11(1):301-4. PubMed ID: 1850218 [TBL] [Abstract][Full Text] [Related]
25. Effect of UTP sugar and base modifications on vaccinia virus early gene transcription. Mohamed MR; Piacente SC; Dickerman B; Niles EG Virology; 2006 Jun; 349(2):359-70. PubMed ID: 16460779 [TBL] [Abstract][Full Text] [Related]
26. Pharmacological and biochemical interactions of N-(phosphonacetyl)-L-aspartate and 5-fluorouracil in beagles. Miller AA; Moore EC; Hurlbert RB; Benvenuto JA; Loo TL Cancer Res; 1983 Jun; 43(6):2565-70. PubMed ID: 6189583 [TBL] [Abstract][Full Text] [Related]
27. Restriction of vaccinia virus replication in CHO cells occurs at the stage of viral intermediate protein synthesis. Ramsey-Ewing A; Moss B Virology; 1995 Feb; 206(2):984-93. PubMed ID: 7856109 [TBL] [Abstract][Full Text] [Related]
28. The enhancement of the frequency of resistance to N-phosphonoacetyl-L-aspartate and methotrexate by 1-beta-D-arabinofuranosylcytosine: the effect of dipyridamole. Goz B; Jeffs L J Pharmacol Exp Ther; 1994 Aug; 270(2):480-4. PubMed ID: 8071840 [TBL] [Abstract][Full Text] [Related]
29. The inhibition of HeLa cell RNA synthesis following infection with vaccinia virus. Pedley S; Cooper RJ J Gen Virol; 1984 Oct; 65 ( Pt 10)():1687-97. PubMed ID: 6208316 [TBL] [Abstract][Full Text] [Related]
30. Aurintricarboxylic acid inhibits the early stage of vaccinia virus replication by targeting both cellular and viral factors. Myskiw C; Deschambault Y; Jefferies K; He R; Cao J J Virol; 2007 Mar; 81(6):3027-32. PubMed ID: 17192307 [TBL] [Abstract][Full Text] [Related]
32. Synthesis and biological evaluation of S-acyl-3-thiopropyl prodrugs of N-phosphonoacetyl-L-aspartate (PALA). Gagnard V; Leydet A; Le Mellay V; Aubenque M; Morère A; Montero JL Eur J Med Chem; 2003 Oct; 38(10):883-91. PubMed ID: 14575935 [TBL] [Abstract][Full Text] [Related]
33. Depletion of blood plasma cytidine due to increased hepatocellular salvage in D-galactosamine-treated rats. Holstege A; Manglitz D; Gerok W Eur J Biochem; 1984 Jun; 141(2):339-44. PubMed ID: 6734601 [TBL] [Abstract][Full Text] [Related]
34. Mechanism-based model for tumor drug resistance. Kuczek T; Chan TC Cancer Chemother Pharmacol; 1992; 30(5):355-9. PubMed ID: 1505073 [TBL] [Abstract][Full Text] [Related]
35. Gene amplification causes overproduction of the first three enzymes of UMP synthesis in N-(phosphonacetyl)-L-aspartate-resistant hamster cells. Wahl GM; Padgett RA; Stark GR J Biol Chem; 1979 Sep; 254(17):8679-89. PubMed ID: 381311 [TBL] [Abstract][Full Text] [Related]
36. Unexpected synergy between N-phosphonacetyl-L-aspartate and cytidine against human tumor cells. Chan TC; Howell SB Eur J Cancer Clin Oncol; 1989 Apr; 25(4):721-7. PubMed ID: 2714348 [TBL] [Abstract][Full Text] [Related]
38. Phase I clinical study of N-(phosphonacetyl)-L-aspartic acid (PALA). Valdivieso M; Moore EC; Burgess AM; Marti JR; Russ J; Plunkett W; Loo TL; Bodey GP; Freireich EJ Cancer Treat Rep; 1980; 64(2-3):285-92. PubMed ID: 7407763 [No Abstract] [Full Text] [Related]
39. A novel mechanism for resistance to the antimetabolite N-phosphonoacetyl-L-aspartate by Helicobacter pylori. Burns BP; Mendz GL; Hazell SL J Bacteriol; 1998 Nov; 180(21):5574-9. PubMed ID: 9791105 [TBL] [Abstract][Full Text] [Related]
40. Collateral sensitivity to N-(phosphonacetyl)-L-aspartic acid in a line of P388 leukemia cells selected for resistance to L-(alpha S, 5S)-alpha-amino-3- chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin). Ardalan B; Jayaram HN; Johnson RK Cancer Res; 1983 Apr; 43(4):1598-601. PubMed ID: 6831405 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]